Deals and Financings   MabPlex, a Yantai biologics CDMO, completed a $59 million Series A round for its biologics development and manufacturing services; Tyto Care, an Israeli telehealth company, raised $9 million from a group that includes China investors for its internet-enabled "home doctor visits"; Ascletis Pharma of Hangzhou acquired China rights to a Suzhou Alphamab anti-PD-L1 candidate for hepatitis B and other viral diseases; Bio-Thera Solutions, a Guangzhou biopharma, out-licensed marketing rights for its Avastin biosimilar to India 's Cipla in specified emerging markets; Luye Pharma out-licensed mainland China marketing rights for its anti-cholesterol Xuezhikang capsules to AstraZeneca China ; Nanning Xinzizhu Trading acquired China distribution rights to a medical device aimed at treating chronic wounds from AOTI of Oceanside, CA; Company News   Boehringer Ingelheim has begun an expansion of its Shanghai biologic contract manufacturing facility to prepare for commercial production; Trials and Approvals   Ironwood Pharma announced China approved its treatment for irritable bowel syndrome with constipation, which will be marketed in China by AstraZeneca; Cellular Biomedicine reported that its off-the-shelf therapy for Knee Osteoarthritis (KOA) was approved to start a China Phase II trial; Suzhou Innovent Biologics has dosed the first patient in a China Phase I clinical trial of its anti-CD47 mAb, an inhibitor of the "Don't Eat Me" pathway; BeiGene, a Beijing oncology biopharma, was granted Breakthrough Therapy designation in the US for its Bruton’s tyrosine kinase (BTK) inhibitor. Stock Symbols: (HK; 1672) (BSE: 500087) (HK: 8126) (NYSE: AZN) (NSDQ: IRWD) (NYSE: AZN) (NSDQ: CBMG) (HK: 01801) (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //